<description>Dr. Tomasz Beer, MD, chief medical officer at Exact Sciences, joins HealthLeaders for a discussion on the clinical research behind Cancerguard tests and how they enable health systems to detect multiple deadly cancers early, streamline diagnostic workflows, and deliver proactive, value-based care.

Information presented is not clinical, diagnostic, or treatment advice for any particular patient. Providers should use their clinical judgement and experience when deciding how to diagnose or treat patients. Exact Sciences does not recommend or endorse any particular course of treatment or medical choice.

The Cancerguard test was developed, and the performance characteristics validated by Exact Sciences Laboratories following College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) regulations. This test has not been cleared or approved by the US Food and Drug Administration. The test is performed at Exact Sciences Laboratories. Exact Sciences Laboratories is accredited by CAP, certified under CLIA regulations, and qualified to perform high-complexity clinical laboratory testing.</description>

Dr. Tomasz Beer, MD, chief medical officer at Exa…

Dr. Tomasz Beer, MD, chief medical officer at Exact Sciences, joins HealthLeaders for a discussion on the clinical research behind Cancerguard tests and how they enable health systems to detect multiple deadly cancers early, streamline diagnostic workflows, and deliver proactive, value-based care.

Information presented is not clinical, diagnostic, or treatment advice for any particular patient. Providers should use their clinical judgement and experience when deciding how to diagnose or treat patients. Exact Sciences does not recommend or endorse any particular course of treatment or medical choice.

The Cancerguard test was developed, and the performance characteristics validated by Exact Sciences Laboratories following College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) regulations. This test has not been cleared or approved by the US Food and Drug Administration. The test is performed at Exact Sciences Laboratories. Exact Sciences Laboratories is accredited by CAP, certified under CLIA regulations, and qualified to perform high-complexity clinical laboratory testing.

Why Health Systems Are Turning to Cancerguard for Early Cancer Detection

<description>Get insights on digital transformation and the future of clinician-centered AI with Ed Lee, MD, MPH, chief medical officer at Nabla.</description>

Get insights on digital transformation and the fu…

Get insights on digital transformation and the future of clinician-centered AI with Ed Lee, MD, MPH, chief medical officer at Nabla.

Jason Spring, vice president of Vizient Member Ne…

Jason Spring, vice president of Vizient Member Networks, joins HealthLeaders editor Jay Asser to discuss how the role of healthcare boards is shifting amid rapid industry change, and how effective governance can shape safer, stronger organizations.

Redefining Governance: How Boards Shape Sustainable Success

<description>David Harding, senior vice president, pipeline product management at Exact Sciences, joins HealthLeaders for a discussion on how to help health system leaders understand the foundation of Multi-Cancer Early Detection (MCED) and how it can impact cancer diagnosis, drive innovation and improve patient outcomes.

Information presented is not clinical, diagnostic, or treatment advice for any particular patient. Providers should use their clinical judgement and experience when deciding how to diagnose or treat patients. Exact Sciences does not recommend or endorse any particular course of treatment or medical choice.</description>

David Harding, senior vice president, pipeline pr…

David Harding, senior vice president, pipeline product management at Exact Sciences, joins HealthLeaders for a discussion on how to help health system leaders understand the foundation of Multi-Cancer Early Detection (MCED) and how it can impact cancer diagnosis, drive innovation and improve patient outcomes.

Information presented is not clinical, diagnostic, or treatment advice for any particular patient. Providers should use their clinical judgement and experience when deciding how to diagnose or treat patients. Exact Sciences does not recommend or endorse any particular course of treatment or medical choice.

Unlocking the Potential of Multi-Cancer Early Detection

<description>Chase McGrath, vice president of product at Aspirion, joins HealthLeaders editor Jay Asser to guide revenue cycle leaders through the strategic adoption of AI for denials management, offering both the why and the how behind successful implementation.</description>

Chase McGrath, vice president of product at Aspir…

Chase McGrath, vice president of product at Aspirion, joins HealthLeaders editor Jay Asser to guide revenue cycle leaders through the strategic adoption of AI for denials management, offering both the why and the how behind successful implementation.

Utilizing AI to Transform Denials Management

The healthcare industry’s leading source for news, intelligence, and strategy for senior executives.

HealthLeaders Podcast

Details

Recent Episodes